Human Complement Component C5/C5a Antibody
R&D Systems, part of Bio-Techne | Catalog # AF2037
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Neutralization, Western Blot
Cited:
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
E. coli-derived recombinant human Complement Component C5a
Thr678-Arg751
Accession # P01031
Thr678-Arg751
Accession # P01031
Specificity
Detects human Complement Component C5/C5a in direct ELISAs and Western blots. In Western blots, approximately 5% cross-reactivity with recombinant mouse Complement Component C5a is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human Complement Component C5/C5a Antibody
N-Acetyl-beta -D-Glucosamini-dase Release Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody.
Recombinant Human Complement Component C5a (Catalog # 2037-C5) induces N-acetyl- beta -D-glucosaminidase release in the the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line in a dose-dependent manner (orange line). N-Acetyl-beta -D-Glucosamin-idase Release elicited by Recombinant Human Complement Component C5a (15 ng/mL) is neutralized (green line) by increasing concen-trations of Goat Anti-Human Complement Component C5a Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2037). The ND50 is typically 0.15-0.75 µg/mL in the presence of cytochalasin-B.Applications for Human Complement Component C5/C5a Antibody
Application
Recommended Usage
Western Blot
0.1 µg/mL
Sample: Recombinant Human Complement Component C5a (Catalog # 2037-C5)
Sample: Recombinant Human Complement Component C5a (Catalog # 2037-C5)
Neutralization
Measured by its ability to neutralize Complement Component
C5a-induced N-acetyl-beta -D-glucosaminidase release in the dibutyryl cyclic-AMP
differentiated U937 human histiocytic lymphoma cell line. Gerard, NP and Gerard, C. (1990) Biochemistry
29:9274. The Neutralization Dose (ND50) is
typically 0.15-0.75 μg/mL in the presence of 15 ng/mL Recombinant Human
Complement Component C5a and cytochalasin‑B.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Complement Component C5/C5a
Human complement 5a (C5a) is an enzymatically generated glycoprotein that belongs to a family of structurally and functionally related proteins known as anaphylatoxins. C5a is a 74 amino acid (aa) peptide that is created by the activity of C5a convertase on the C5 alpha-chain (1, 2). Human C5a has four alpha-helices plus three intrachain disulfide bonds that create a triple loop structure (3). In serum, proteolytic processing removes the C-terminal arginine, creating a low activity C5adesArg74 molecule (1). Human C5a is 60% and 54% aa identical to mouse and rat C5a, respectively. C5a binds to a signaling G-protein coupled receptor (C5aR/CD88) and a nonsignaling GPCR termed C5L2 (4). Activation of Cd88 results in neutrophil chemotaxis and endothelial cell activation (1, 5). It also triggers an oxidative burst in macrophages and neutrophils, and induces release of histamine in basophils and mast cells.
References
- Gerard, C. and N.P. Gerard (1994) Annu. Rev. Immunol. 12:775.
- DiScipio, R.G. et al. (1983) J. Biol. Chem. 258:10629.
- Huber-Lang, M.S. et al. (2003) J. Immunol. 170:6115.
- Okinaga, S. et al. (2003) Biochemistry 42:9406.
- Gerard, N.P. and C. Gerard (2002) Curr. Opin. Immunol. 14:705.
Alternate Names
C5
Gene Symbol
C5
UniProt
Additional Complement Component C5/C5a Products
Product Documents for Human Complement Component C5/C5a Antibody
Product Specific Notices for Human Complement Component C5/C5a Antibody
For research use only
Loading...
Loading...
Loading...
Loading...